-
EU green light for Cimzia to treat psoriasis
pharmatimes
July 04, 2018
The European Medicines Agency has approved a label extension for UCB’s Cimzia allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy.
-
US approves UCB’s Cimzia for psoriasis
pharmatimes
June 06, 2018
US regulators have expanded the reach of UCB’s Cimzia, allowing its use to treat adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
-
Lilly's Taltz (ixekizumab) Receives the First U.S. FDA Approval for Label Update to Include Data for Psoriasis Involving the Genital Area
drugs
May 31, 2018
Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved a label update for Taltz (ixekizumab) injection 80 mg/mL to include data in psoriasis involving the genital area.
-
US green lights new biologic for psoriasis
pharmatimes
March 23, 2018
The US Food and Drug Administration has approved Sun Pharma’s Ilumya as a new treatment option for adults with moderate-to-severe plaque psoriasis.
-
Sun Pharma Announces U.S. FDA Approval of ILUMYA? (tildrakizumab-asmn) for the Treatment of Moderate
biospace
March 22, 2018
?Sun Pharmaceutical Industries?Ltd. today announced that FDA has approved ILUMYA? for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy
-
Next Generation Biologics, Janssen's Tremfya, Eli Lilly's Taltz, and Novartis' Cosentyx, Raising the
biospace
March 09, 2018
The past three years have brought with them a flurry of branded biologic approvals in dermatology, including four biologics for psoriasis alone
-
In a crowded market, AbbVie may still have a best-in-class psoriasis prospect up its sleeve: analyst
fiercepharma
December 07, 2017
The last few years have seen a wave of new biologics take the psoriasis market by storm. But a best-in-class product may still be on its way, one analyst says.
-
Vanilla compound found to prevent psoriasis
pharmafile
December 06, 2017
Psoriasis is a big pharmaceutical market, it’s the most common autoimmune disease in the US and as many as 7.5 million citizens have the condition.
-
Taltz Receives FDA Approval for Active Psoriatic Arthritis
americanpharmaceuticalreview
December 06, 2017
Eli Lilly and Company announced the U.S. Food and Drug Administration (FDA) has approved?Taltz (ixekizumab)?injection 80 mg/mL for the treatment of adults with active psoriatic arthritis (PsA).
-
Janssen launches Tremfya in UK to treat psoriasis
pharmaceufical-technology
November 27, 2017
Janssen has announced the availability of Tremfya (guselkumab) in the UK for adults with moderate-to-severe plaque psoriasis.
ALL
Pharma?in?China
Pharma?Experts
Market News
Products Guide
Brand Story
Pharma Sources Insight January 2025
